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Caution! Diagnosis creep
colleagues and I analysed recent changes made 
by expert panels to the definitions of 14 common 
conditions, including hypertension, depression and 
Alzheimer’s disease.5 Of 16 publications from the 
panels, only one proposed a narrower definition, for 
five the impacts were unclear, and 10 proposed an 
expanded definition - pre-diseases were created, 
thresholds were lowered, or diagnostic processes 
changed to enable earlier diagnosis. In no case did 
a panel rigorously investigate and report on the 
potential danger that some people may be caught 
unnecessarily by the newly widened definitions. 
Among the panels that disclosed competing interests, 
75% of panel members had multiple financial ties 
to a median of seven drug companies each. These 
members were paid by companies for activities 
like speaking, consulting, advising or researching. 
This is in direct contrast to recommendations from 
organisations like the US Institute of Medicine 
for more independence among those who 
write guidelines.6
For instance, among the blood pressure guideline 
panel that in 2003 created ‘pre-hypertension’, 80% of 
members disclosed ties to 12 companies each.5 Eight 
of the 11 members had financial ties to pharmaceutical 
companies that sold drugs for hypertension.
Over half of the members of the 2011 joint US National 
Institute on Aging – Alzheimer’s Association panel 
that described ‘pre-dementia’ and defined ‘pre-
clinical’ Alzheimer’s disease had financial ties to a 
median of five companies.5 Similarly for the 2012 
psychiatric panels, which widened the definitions 
of depression and attention deficit hyperactivity 
disorder, over half disclosed links to companies, 
including those that could directly benefit from 
expanded patient populations.5
The decisions made by these heavily conflicted panels 
are not abstract academic exercises. They ultimately 
influence whether or not an individual is labelled as 
‘diseased’, changing their life’s narrative. Moreover, 
decisions that expand patient populations profoundly 
affect where we spend our health resources.
Health professionals should be more aware, and 
patients and the public better informed, about 
the controversy surrounding many contemporary 
definitions of disease. Diagnostic criteria are not set 
in stone – they are regularly changed, often with 
the best of intentions, but are also often rigorously 
challenged because of the potential for unintended 
Twenty years ago British GP Iona Heath observed that 
one of the key roles of the GP was to help protect 
people from the unnecessary diagnosis of disease.1 
Perhaps the biggest challenge for doctors who take 
that role seriously comes from expanding disease 
definitions. The current definition of ‘chronic kidney 
disease’ labels 10% of the adult population as having 
the condition.2 New criteria almost triple the number 
of pregnant women labelled as having gestational 
diabetes.3 Thresholds defining attention deficit 
hyperactivity disorder continue to fall, meaning more 
children and adults will be diagnosed.4
We are labelling more and more healthy people as 
sick and building bigger potential markets for those 
selling medicines. For some of the newly labelled 
patients there will no doubt be benefits, but for 
others with mild problems or at very low risk of 
illness, a diagnosis can bring more harm than good, 
leading to overtreatment and wasting precious 
resources that could be better directed to those in 
genuine need.
The process of broadening definitions can be 
described as ‘diagnosis creep’ and often results 
from guidelines prepared by expert panels. In 2013 
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NPS MedicineWise, the publisher of Australian 
Prescriber, has decided to cease publication of the 
journal in print. In addition, the journal’s website 
australianprescriber.com, established in 1996, 
will be replaced by a new website hosted by NPS 
MedicineWise. The Australian Prescriber team would 
like to thank Greg Buchberger (GBI Creative) who has 
been the journal’s webmaster for over a decade. In 
future, health professionals who wish to continue to 
read Australian Prescriber need to register at nps.org.au/australianprescriber. 
This penultimate issue of the printed Australian Prescriber has a focus on 
osteoporosis. Angela Sheu and Terry Diamond discuss diagnosis, while Akhil Gupta 
and Lyn March review its management. Chris Daly describes the dental problems 
that can result from the treatment of osteoporosis.
While relatively few patients with minimal trauma fractures are investigated for 
osteoporosis, in other conditions there is overdiagnosis. Ray Moynihan discusses 
this diagnosis creep.
Borderline personality disorder is often undetected. While management can be 
challenging, Andrew Chanen and Katherine Thompson tell us that drugs are not 
first-line therapy.
Managing menstrual problems in women with intellectual disability may also seem 
challenging, but Jane Tracy, Sonia Grover and Sandra Macgibbon provide helpful 
advice. The approach to management should be the same as it is in other women.
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both benefits and harms before they shift diagnostic 
thresholds. In line with the Institute of Medicine’s 
recommendations for more independence in guideline 
panels,6 a new approach must surely also mean an 
end to panel members being speakers or consultants 
for companies that directly benefit from their 
deliberations on diagnosis. While it is more difficult to 
find unconflicted experts, practical models do exist, 
including the National Institutes of Health consensus 
development panels.12
These efforts to reform the way diseases and 
diagnostic thresholds are set are happening 
concurrently with related initiatives to combat medical 
excess, like the Choosing Wisely Australia campaign. 
This aims to reduce use of unnecessary tests and 
treatments.15
Finally, in the interest of protecting people from 
the dangers of diagnosis creep, one might take the 
provocative advice of Dr Iona Heath. Addressing a 
symposium about the problem of too much medicine 
in Canada in 2014, Dr Heath prescribed this solution: 
‘Whenever I see the sort of guidelines that are, right 
now, driving overdiagnosis and overtreatment, I think 
of this: our responsibility not to follow the rules.’16 
Conflict of interest: Ray Moynihan is a member of the 
scientific committee that is organising the international 
scientific conference Preventing Overdiagnosis. He is also 
a member of the planning committee for the Australian 
Preventing Overdiagnosis and Overuse meetings.
harms. A peer-reviewed series in the BMJ is currently 
examining expanding disease definitions and the 
risk of overdiagnosis. The series has included articles 
on the evidence underpinning the controversy over 
gestational diabetes,3 attention deficit hyperactivity 
disorder,4 chronic kidney disease,7 pre-dementia,8 mild 
hypertension9 and pulmonary embolism.10
With gestational diabetes for example, proposals to 
lower diagnostic thresholds and dramatically expand 
the patient population have generated ongoing 
criticism that too many women will be labelled 
unnecessarily.11 The proposals have been rejected 
by an independent panel constituted under the US 
National Institutes of Health consensus development 
conference series.12
Health professionals can help to expose and challenge 
diagnosis creep, and improve disease definitions. A 
group of doctors in the UK has successfully lobbied 
the Royal College of General Practitioners to set up 
a standing committee to address overdiagnosis,13 
and similar moves are afoot in Australia. Across 
Europe the new ‘quaternary prevention’ movement 
is also gathering strength within primary care. This 
doctor-led movement is aimed at preventing people 
receiving diagnoses that may bring them more harm 
than good.14
Globally, efforts are underway from a range of 
organisations including the Guidelines International 
Network, to produce new guidelines for guidelines, 
to encourage expert panels to rigorously examine 
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